

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)



(10) International Publication Number
WO 2021/207597 A1

(51) **International Patent Classification:**
A61K 39/395 (2006.01) *C12N 5/06* (2006.01)
C07K 16/18 (2006.01) *C12N 15/11* (2006.01)
63/143,456 29 January 2021 (29.01.2021) US
63/147,495 09 February 2021 (09.02.2021) US
63/148,754 12 February 2021 (12.02.2021) US
63/150,413 17 February 2021 (17.02.2021) US
(21) **International Application Number:**
PCT/US2021/026574 63/152,054 22 February 2021 (22.02.2021) US
63/163,400 19 March 2021 (19.03.2021) US
(22) **International Filing Date:**
09 April 2021 (09.04.2021)
(25) **Filing Language:** English
(26) **Publication Language:** English
(30) **Priority Data:**
63/008,545 10 April 2020 (10.04.2020) US
63/021,589 07 May 2020 (07.05.2020) US
63/046,313 30 June 2020 (30.06.2020) US
63/112,122 10 November 2020 (10.11.2020) US
63/138,886 19 January 2021 (19.01.2021) US
(71) **Applicant:** ADAGIO THERAPEUTICS, INC. [US/US];
303 Wyman Street, Suite 300, Waltham, MA 02451 (US).
(72) **Inventors:** BELK, Jonathan; c/o Adimab, LLC, 7 Lucent
Drive, Lebanon, NH 03766 (US). DEVEAU, Laura; c/o
Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766 (US).
RAPPAZZO, C., Garrett; c/o Adimab, LLC, 7 Lucent
Drive, Lebanon, NH 03766 (US). WALKER, Laura; c/o
Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766 (US).
WEC, Anna; c/o Adimab, LLC, 7 Lucent Drive, Lebanon,
NH 03766 (US).

(54) **Title:** COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOF

ADI ID	VH Protein SEQ ID NO.	VH FR1 Protein SEQ ID NO.	VH CDR1 Protein SEQ ID NO.	VH FR2 Protein SEQ ID NO.	VH CDR2 Protein SEQ ID NO.	VH FR3 Protein SEQ ID NO.	VH CDR3 Protein SEQ ID NO.	VH FR4 Protein SEQ ID NO.	VH DNA SEQ ID NO.
ADI-55688	102	103	104	105	106	107	108	109	110
ADI-55689	202	203	204	205	206	207	208	209	210
ADI-55690	302	303	304	305	306	307	308	309	310
ADI-55691	402	403	404	405	406	407	408	409	410
ADI-55692	502	503	504	505	506	507	508	509	510
ADI-55693	602	603	604	605	606	607	608	609	610
ADI-55694	702	703	704	705	706	707	708	709	710
ADI-55695	802	803	804	805	806	807	808	809	810
ADI-55696	902	903	904	905	906	907	908	909	910
ADI-55697	1002	1003	1004	1005	1006	1007	1008	1009	1010
ADI-55698	1102	1103	1104	1105	1106	1107	1108	1109	1110
ADI-55699	1202	1203	1204	1205	1206	1207	1208	1209	1210
ADI-55700	1302	1303	1304	1305	1306	1307	1308	1309	1310
ADI-55701	1402	1403	1404	1405	1406	1407	1408	1409	1410
ADI-55702	1502	1503	1504	1505	1506	1507	1508	1509	1510
ADI-55703	1602	1603	1604	1605	1606	1607	1608	1609	1610
ADI-55704	1702	1703	1704	1705	1706	1707	1708	1709	1710
ADI-55705	1802	1803	1804	1805	1806	1807	1808	1809	1810
ADI-55706	1902	1903	1904	1905	1906	1907	1908	1909	1910
ADI-55707	2002	2003	2004	2005	2006	2007	2008	2009	2010
ADI-55708	2102	2103	2104	2105	2106	2107	2108	2109	2110
ADI-55709	2202	2203	2204	2205	2206	2207	2208	2209	2210
ADI-55710	2302	2303	2304	2305	2306	2307	2308	2309	2310
ADI-55711	2402	2403	2404	2405	2406	2407	2408	2409	2410
ADI-55712	2502	2503	2504	2505	2506	2507	2508	2509	2510

FIG. 1A

(57) **Abstract:** The present disclosure is directed to antibodies, and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus (SARS-CoV-S) and/or the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies and antibodies that bind to and/or compete for binding to the same linear or conformational epitope(s) on CoV-S. Further disclosed are conjugates of anti-CoV-S antibodies, and binding fragments thereof, conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure include the use of anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses, or the S protein thereof, and conditions where neutralization or inhibition of coronaviruses, or the S protein thereof, would be therapeutically and/or

[Continued on next page]

(74) **Agent: CLARKE, Marcie B.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))